Application of Advate® for the treatment of patients with hemophilia A
| Autor: | N. A. Fedorova, E. A. Filatova, Tat'yana Zabolotskikh, T. V. Esenina, K. M. Mishkurova, Valeriy Voytsekhovskiy, E. S. Sagir, I. P. Baturskaya, T. V. Sharanda |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Pulmonary and Respiratory Medicine
Drug congenital hereditary and neonatal diseases and abnormalities Pediatrics medicine.medical_specialty medicine.diagnostic_test business.industry media_common.quotation_subject Hemophilic arthropathy Physical examination Secondary prophylaxis Retrospective cohort study Coagulation hemic and lymphatic diseases On demand Pediatrics Perinatology and Child Health medicine Observational study business media_common |
| Zdroj: | Bulletin Physiology and Pathology of Respiration. 1:77-86 |
| ISSN: | 1998-5029 |
| DOI: | 10.36604/1998-5029-2020-77-77-86 |
| Popis: | Aim. A retrospective study of the efficacy and safety of the use of the Advate® (Oсtoсog alpha) factor VIII (FVIII) drug for the preventive treatment and reduction of acute bleeding episodes in patients with hemophilia A living in the Amur Region. Materials and methods. A retrospective observational monocentric initiative study of the results of the use of the Advate® was performed, which was carried out as part of routine clinical practice (2017-2019). Two comparison groups were formed; each included 14 patients with severe and moderate forms of hemophilia. Each group consists of 2 subgroups: A – 5 patients over the age of 18 years with hemophilic arthropathy, receiving tertiary prophylaxis (1A – with the Advate and 2A – with other foreign drugs FVIII); B – 9 patients under the age of 18 years, without signs of irreversible joint damage, receiving primary and secondary prophylaxis (1B – with Advate and 2B with other foreign drugs FVIII). The work used the results of an individual interview and clinical examination of patients with hemophilia A, data from outpatient records and diaries kept by patients or their parents and in which certain events were recorded during the period of prophylactic treatment with coagulation factor VIII (FVIII) drugs. Results. As a result of the study, data were obtained that the Advate during both prophylactic therapy and reduction of acute bleeding is not inferior in effectiveness to other FVIII concentrates. In patients of subgroup 1A (with the presence of hemophilic arthropathy), it was possible to reduce the frequency of bleeding compared to the period when these patients received therapy “on demand” by 97%, which corresponds to patients from subgroup 2A. Preventive therapy with commercial FVIII drugs, including Advate, started in childhood, made it possible to avoid severe, life-threatening options for bleeding and the development of orthopedic pathology. Advate therapy for patients with hemophilia A was not accompanied by the development of toxic, thrombogenic and immunogenic reactions. Conclusion. Advate® can be effectively used for the prevention and reduction of acute bleeding in patients with hemophilia. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|